Lyon, France — October 31, 2025 — Leads & Copy — Poxel SA has appointed Yves Decadt to its Board of Directors to bolster its strategic and commercial organization, following governance changes on July 31. The appointment will be submitted for shareholder approval at the next Annual General Meeting.
Decadt brings over 25 years of pharmaceutical industry experience, including nearly 20 years at Johnson & Johnson in Global Business Development. He has also held senior executive positions in biopharma and medtech companies. Since August 2025, Decadt has consulted with Poxel’s teams, supporting partnership discussions and assessing the commercial potential of Poxel’s assets.
To comply with gender balance requirements, Nicolas Trouche resigned from his Director position, paving the way for Decadt’s appointment. Trouche, CEO of Poxel, expressed delight at Decadt’s appointment, citing his expertise in strategic partnerships as invaluable for strengthening value creation.
Poxel SA is a biopharmaceutical company focused on treatments for chronic serious diseases, including MASH and rare disorders. Its product portfolio includes PXL065 for MASH, PXL770 for adrenoleukodystrophy (ALD) and autosomal dominant polycystic kidney disease (ADPKD), and TWYMEEG® (Imeglimin) for type 2 diabetes in Japan. Poxel has a strategic partnership with Sumitomo Pharma for Imeglimin in Japan.
For more information, please visit: www.poxelpharma.com
Nicolas Trouche, Chief Executive Officer of Poxel
Source: Poxel SA
